StrataStem

StrataStem is an innovative spin-off biotechnology company at the forefront of Alzheimer's disease (AD) research, developing an intelligent Phenotype-Genotype (iPG) drug screening platform to identify suitable treatments for AD. StrataStem is modeling diseases using our iPG drug screening technology, including familial and sporadic (late-onset) dementia, schizophrenia, epilepsy, and other difficult-to-treat neurological disorders.